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 ABSTRACT 
Oral cancer is the sixth most frequently occurring cancer worldwide. The recurrence of oral 
cancer purported to Cancer Stem cells.  Prospective identification, characterization, and 
isolation of markers is an important aspect in the potential identification and isolation of 
CSCs. CD44, a hyaluronic acid receptor, is one of the most commonly studied surface 
markers, which is expressed by almost every tumour cell. The expression of CD44 in oral 
cancer tissue was analysed by using immunohistochemical technique.  Three different groups 
of oral cancer tissue were taken i.e. well differentiated, moderately differentiated, & poorly 
differentiated. The poorly differentiated tissue have high metastasis properties so the 
expression of the marker is very high on those tissues as compare two other two. From the 
IHC study we found that the CD44 stem cell marker is highly expressed in poorly 
differentiated oral cancer tissue, moderately expressed in moderately differentiated tissue and 
the expression profile is relatively low in well differentiated oral cancer tissue. 
Key Words: Cancer Stem Cells, Stem cell marker, CD44, Immunohistochemistry 
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CHAPTER-1 
1. INTRODUCTION 
Growth of cancerous tissue in oral cavity causes oral cancer. It is also called as mouth 
cancer. The term oral cancer refers to a diverse group of tumors growth from lip, cheek, floor 
of the mouth, hard and soft palate, tongue, pharynx and oral cavity. Oral cancer is the sixth 
most frequently occurring cancer worldwide.In United States, about 29 000 people suffer 
cancer every year. Oral cancer alone accounts for 270 000 new cases annually and 145 500 
annually, the majority of which occur in developing countries. The mortality rates due to oral 
cancer have been increased significantly in developing countries in past few years (Day et al., 
1984; WHO, 1992). The countries reported to be most affected by oral cancer are India, 
Pakistan, Bangladesh, Honk Kong, Singapore, and Phoillipines (Malaowalla et al., 1976).  
Squamous cell carcinoma (SCC) has been identified as the most common type of oral cancer 
till date. It alone accounts for about 90% of the total oral cancers (Walker et al., 2003). 
Although, several surgical techniques and adjuvant therapies have been developed for the 
diagnosis, the prognosis of patients with OSCC remains poor. The main reasons for serious 
delay in the diagnosis of the oral cancer are misdiagnosis, ineffective treatment, problems 
with access to healthcare professionals, and unawareness of the specific biomarkers of OSCC 
(Brouha et al 2005;Scott et al ). Early detection of oral cancer is believed to be the more 
effective way to improve survival. These cancers are largely amendable to curative surgery or 
radiotherapy, with or without concurrent chemotherapy, when diagnosed at an early stage. 
The etiology of tongue SCC is well described. Tobacco use, heavy alcohol consumption, 
poor nutrition, immunocompromised health states and viral infections have all been 
implicated in the carcinogenesis of squamous cell carcinoma of the tongue. Of these risk 
factors, tobacco and alcohol consumption are thought to account for more than 75% of oral 
tongue cancers.Oral cancer results from a variety of factors that operate over time and is 
dependent on each person’s unique response to these factors. The 2 most important 
modifiable risk factors for oral cancer are tobacco and alcohol consumption. Up to 75% of 
oral cancers may be attributed to exposure to tobacco or alcohol. The most commonly 
implicated viruses in oral cancer transformation have been the human papillomavirus (HPV), 
herpes group viruses, and the adenoviruses. HPV and herpes have been the most thoroughly 
studied and are now considered to be the most likely “synergistic viruses” involved in human 
oral cancer. The herpes viruses most often linked to oral cancer are the Epstein-Barr virus 
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(EBV) and cytomegalovirus (CMV); both EBV DNA and CMV DNA have been 
demonstrated in oral carcinomas. 
1.1 SYMPTOMS: 
Common symptoms of oral cancer include: 
 Patches inside mouth or on lips that are white, a mixture of red and white, or red 
White patches (leukoplakia) are the most common. White patches sometimes become 
Malignant. 
 Mixed red and white patches (erythroleukoplakia) are more likely than white patches 
to become malignant. Red patches (erythroplakia) are brightly colored, 
• Bleeding in mouth. 
• Loose teeth 
• Difficulty in swallowing 
• Difficulty wearing dentures 
• A lump neck 
• Difficulty in moving tongue or jaws  
 
                          
              LEUKOPLAKIA                                                                         ERYTHROPLAKIA 
                                               
                                              Fig1.Leukoplakia and Erythroplakia 
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1.2 RISK FACTORS 
 
1.2.1. Tobacco 
 The risk of oral cancer and premalignant lesions increases with the amount of 
tobacco consumed. This increased risk holds for all types and uses of tobacco, whether it is 
smoked as a cigarette, cigar, pipe or bidi (a small, hand-rolled cigarette commonly used in 
Asia), or used smokeless as a chew, plug or snuff. Stopping smoking reduces the risk of oral 
cancer and premalignant lesions, although it may take 10 to 20 years for a former smoker’s 
risk to reduce to that of a nonsmoker. Patients from South Asian countries may also chew 
betel quid or paan, a common habit in their culture. Betel quid is a carcinogenic complex 
mixture of plant components that frequently contains tobacco. 
 
1.2.2 Alcohol 
Alcohol consumption is also a strong risk factor for oral cancer and premalignant 
lesions. The risk increases with increased consumption and duration of use of alcohol. 
Typically, one 8-ounce glass of beer, one 4-ounce glass of wine and 1 ounce of spirits have 
equal amounts of alcohol. Again, the risk of oral cancer decreases when alcohol is no longer 
consumed. But it takes many years for a drinker’s risk to reduce to that of someone who has 
never been a drinker. Tobacco and alcohol consumption work together synergistically, 
increasing the risk of oral cancer to more than 30 time that of those who do not smoke or 
drink. Heavy drinkers and smokers are also more likely to be diagnosed with late-stage 
disease. Ceasing to use tobacco and alcohol greatly reduces the risk of developing oral cancer 
and premalignant lesions. 
 
1.2.3 Human Papilloma Virus 
  Human papilloma virus (HPV) is a strong risk factor for oral cancers, especially when 
the lingual and palatine tonsils, the soft palate and the base of the tongue are involved. There 
are more than 120 types of HPV, but only a few are high-risk factors for oral cancer, 
primarily HPV- 16 and HPV-18. Over 90% of HPV-positive oral cancers are HPV-16 
positive. Since risk factors for HPV infection include having a large number of sexual 
partners and first intercourse at a younger age, changing sexual practices in our society may 
increase the effect of HPV infection on the development of oral cancers and premalignant 
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lesions, especially in younger adults. The combination of smoking and HPV infection and of 
alcohol and HPV infection may have an additive effect. 
 
1.2.4 Diet and Vitamins 
A diet rich in fruits and vegetables, particularly fruit, reduces the risk of oral cancer 
and premalignant lesions.  Several studies have shown that higher levels of vitamin C or 
carotene consumption reduce the risk of oral cancer. 
 
1.3 TREATMENT  
Oral cancer treatment may include surgery, radiation therapy, and chemotherapy 
 
1.3.1 Surgery 
Surgery to remove the tumor in the mouth or throat is a common treatment for oral 
cancer.  
 
1.3.2 Radiation Therapy 
Radiation therapy also called radiotherapy is a type of local therapy. It affects cells 
only in the treated area. Radiation therapy is used alone for small tumors or for patients who 
cannot have surgery. It may be used before surgery to kill cancer cells and shrink the tumor. 
It also may be used after surgery to destroy cancer cells that may remain in the area. 
Radiation therapy uses high-energy rays to kill cancer cells. Doctors use two types of 
radiation therapy to treat oral cancer. 
 
• External radiation: The radiation comes from a machine. Patients go to the hospital or 
clinic once or twice a day, generally 5 days a week for several weeks. 
 
• Internal radiation (implant radiation): The radiation comes from radioactive material 
placed in Seeds, needles, or thin plastic tubes put directly in the tissue. The patient stays in 
the hospital. The Implants remain in place for several days. Usually they are removed before 
the patient goes home. Some people with oral cancer have both kinds of radiation therapy. 
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1.3.3 Chemotherapy  
Chemotherapy (chemo) is a technique that involves the use of anti-cancer drugs that 
are administered into a vein or taken by mouth. These drugs enter the bloodstream and can 
reach cancer that has spread to organs beyond the head and neck.  
It is used in several ways i.e. 
 Chemo (typically combined with radiation therapy)  
 Chemo (combined with radiation therapy, called adjuvant chemotherapy) - given after 
surgery to kill any small deposits of cancer cells that may have been left behind. 
 Chemo (sometimes with radiation, called neoadjuvant or induction chemotherapy) 
used to try to shrink some larger cancers before surgery.  
 Chemo (with or without radiation) can be used to treat cancers that are too large or 
have spread too far to be removed by surgery.  
The chemo drugs used most often for cancers of the oral cavity and oropharynx are: 
Cisplatin, 5-fluorouracil (5-FU), Carboplatin, Paclitaxel (Taxol), Docetaxel (Taxotere), 
Methotrexate, Ifosfamide (Ifex), Bleomycin .Combining drugs shrink tumors more 
effectively. A commonly used combination is cisplatin and 5-FU which is more effective 
than either drug alone in shrinking cancers of the oral cavity and oropharynx. Chemo is 
often given at the same time as radiation (known as chemoradiation). Cisplatin alone is 
usually the preferred chemo drug when given along with radiation. Some doctors prefer 
to give the radiation and chemo before surgery. However, the side effects can be severe 
and may be too much for some patients. 
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CHAPTER-2 
 
2. LITERATURE   REVIEW 
 
2.1 CANCER STEM CELL 
Cancer stem cells are subset of cancer cells which have self renewal capacity and 
contain tumor. It is also called as tumor initiating cells (TIC). The cancer stem cells were first 
demonstrated in acute myelogenous leukemia (AML) in 1994 by John Dick and colleagues. 
Cancer stem cells have been characterized in many different types of human tumors like brain 
tumors, multiple myeloma, colon cancer, prostate cancer, head and neck cancer, melanoma, 
hepatocellular carcinoma (HCC), pancreatic cancer and lung cancer. Cancer stem cells 
originate from normal stem cells and it has multiple mutations. Cancer stem cells   have de-
differentiation and transdifferentiation process. The difference between “stem cells” and 
“cancer stem cell” is that   “cancer stem cells” as “tumor initiating cells” have high 
tumorigenicity and self-renewal ability. Currently, three methods are most used to isolate 
cancer stem cells. These methods include flow cytometry sorting based on surface marker 
expression, sorting as side population (SP), and sphere culture. 
 
There are three main characteristics to identify CSCs: (1) Differentiation, which 
provides the ability to give rise to a heterogeneous progeny, (2) Self-renewal capability that 
maintains an intact stem cell pool for expansion,  (3) Homeostatic control that ensures an 
appropriate regulation between differentiation and self renewal according to the 
environmental stimuli and genetic constraints of each organ tissue, which accounts for the 
tissue specificity of CSCs. Cancer stem cells  divide asymmetrically creating   two different 
cell populations. One population retains the self-renewing properties of the parental cancer 
stem cell and the other population is tumor cell with ability to differentiate but without the 
ability to initiate tumor growth. 
 
2.2 STEM CELL MARKER  
Stem cells are capable of generating a huge number of mature cells through a 
sequential procedure of proliferation and differentiation, at the same time retaining its ability 
to self-renew to maintain the stem cell pool.  In a study conducted by Judd et al (2011), the 
researchers have tried to get an insight into the OSCC disease. Stem cell markers are the type 
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of genes and the protein products are used to isolate and identify stem cell.“Stem cell 
marker” should identify a multipotent single cell capable of recapitulating the heterogeneity 
of the tumor. It has self-renewal capacity; it should have the ability to divide and give rise to 
an exact copy of itself. 
There are four different types of stem cell marker. 
1. Embryonic stem cell marker 
2. Hematopoietic stem cell marker 
3. Mesenchymal/ stromal stem cell marker 
4. Neural stem cell marker 
2.2.1 Embryonic stem cell marker: 
Embryonic stem cell is derived from Embryo. There are different types of ESC 
markers i.e.Oct-4, SSEA. 
2.2.1.1 Oct-4 (octamer-binding transcription factor 4):  
 It identify as a DNA-binding protein that activates gene transcription via a cis-
element which containing the octamer motif (Scholer et al., 1990 ). It is POU transcription 
factors which expressed in totipotent embryonic stem cell and germ cells (Rosner et al., 1990)   
. Oct-4 expression is associated with an undifferentiated phenotype and tumors cell An Oct-4 
expression is required to sustain stem cell self-renewal capacity and pluripotency. Oct-4 is 
not only a master regulator of pluripotency but is also the first and most recognized marker 
used for the identification of totipotent ES cells.  
2.2.1.2 SSEAs (Stage Specific Embryonic Antigens):  
SSEAs are identified by three monoclonal antibodies associated with lacto- and 
globo-series glycolipid . There are different types of SSEAs i.e. SSEAs-1, SSEAs-3, SSEAs-
4.SSEAs-1 is expressed on the surface of preimplantation-stage of the embryos and has been 
found on the surface of teratocarcinoma stem cells. The oviduct epithelium, endometrium and 
epididymis, as well as some areas of the brain and kidney tubules in adult mice have also 
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been shown to be reactive with SSEA-1 Abs. SSEA-3 and -4 are synthesized during 
oogenesis and are present in the membranes of oocytes, zygotes and early cleavage-stage 
embryos. 
2.2.2 Hematopoietic stem cell markers 
Hematopoietic Stem Cells are morphologically similar to white blood cells (WBCs). 
There are different types of HSC markers i.e. CD34, CD133, ABCG2, SCA-1. 
2.2.2.1 CD34:  
The cell surface CD34 has been expressed on a small fraction of human bone marrow 
cells. There are two different types of CD34 marker are there i.e. CD34
+
 & CD34
-
.The 
CD34
+
-enriched cell population from marrow is responsible for most of the hematopoietic 
activity. Therefore CD34 has been considered to be the most critical marker for 
hematopoietic stem cells (HSCs). CD34 expression on primitive cells is down-regulated as 
they differentiate into mature cells. Although, CD34 plays a significant role in early 
hematopoiesis, Osawa et al. first demonstrated that CD34 HSCs could be negative.  Human 
CD34
-
 cells have low level of engraftment and hematopoietic capacity. CD34
-
 cell population 
have repopulating activity in fetal sheep.  Both murine and human CD34
+ 
cells may be 
derived from CD34
-
 cells. The possibility of HSCs may be CD34
+
 or CD34
-
 and expression 
of CD34 more primitive stem cells.   Almost all clinical and experimental protocols including 
ex vivo culture, gene therapy, and HSC transplantation are currently designed for cell 
populations enriched for CD34
+
 cells.  
2.2.2.2 CD133:  
 It is a glycosylated protein containing five transmembrane domains and is identify by 
the AC133 monoclonal Ab, which recognizes a CD34
+
 subset of human HSCs (Yin, et al. 
1997;) Recently ACD133 isoform has been cloned and identified the original surface the 
antigen which is recognized by the AC133 Ab. CD133 alternative to CD34 for HSC 
selection.  According to multilineage capacity A CD133
+
 enriched subset can be expanded in 
a similar as a CD34
+
 enriched subset (Kobari, et al., 2001). Recent studies have evidence that 
CD133 expression is not limited to primitive blood cells, but defines unique cell populations 
in non-hematopoietic tissues. CD133
+
 progenitor cells from peripheral blood which induced 
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to differentiate into endothelial cells in vitro. In human neural stem cells can be directly 
isolated by using an anti-CD133 Ab (Uchida, et al. 2000).  
2.2.2.3 ABCG2 
  ABCG2 (ATP-binding cassette superfamily G member 2) is a determinant of the 
Hoechst-negative phenotype of side population (SP) cells.ABCG2 is a member of ABC 
transporters family and was first identified in a breast cancer cell line. It belongs to the half-
transporter group and is unique as it is localized to the plasma membrane. The expression of 
ABCG2 appears greatest on CD34
-
 cells and is down-regulated of CD34 on the cell surface. 
Down-regulation in ABCG2 expression is also observed in various committed hematopoietic 
progenitors. ABCG2 may therefore serve as a more promising marker than CD34 for 
primitive HSC isolation and characterization. The expression pattern of ABCG2 is not 
limited to HSC. ABCG2 expression exclusively characterizes the Hoechst SP phenotype in 
cells from diverse sources, including bone marrow, skeletal muscle and ES cells. The 
potential plasticity of SP cells has been demonstrated by cardiomyocytes and muscle 
regenerated from transplanted bone marrow- which derived SP cells. Exclusive expression of 
ABCG2 on SP cells suggests that ABCG2 is a potential marker for positive selection of 
pluripotent stem cells from various adult sources. ABCG2 have playing a functional role in 
developmental stem cell biology. 
 
2.2.2.4 Sca-1 
Sca-1 (stem cell antigen 1), is a phosphatidylinositol-anchored protein, is a member of 
the Ly-6 antigen family (Bunting, et al., 2002).  Sca-1 is the most recognized HSC marker in 
mice. It is expressed on multipotent HSCs. An anti-Sca-1 Ab is frequently used negative 
selection and expressed the number of cell surface markers. The characteristic of 
differentiated cells of hematolymphoid lineages (Lin
-
) is to identify and isolate murine HSCs. 
Sca-1
+
 HSCs is found in the adult bone marrow, fetal liver and mobilized peripheral blood 
and spleen within the adult animal. Sca-1 also discovered several non-hematopoietic tissues, 
and can it is use in enrich progenitor cell populations. Sca-1 also involved in regulating both 
B cell and T cell activation (Codias   et al., 1990). 
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2.2.3 Mesenchymal/ stromal stem cell marker 
Mesenchymal stem cells (MSCs) are multipotent cell which derived progenitor cells. 
They have the capacity to differentiate into cells that compose adipose, bone, cartilage, and 
muscle tissue. Adult mesenchymal stem cells can be isolated from the stroma of the bone 
marrow.so it is also called as stromal cell. STRO-1 & CD44 comes under the mesenchymal 
stem cell marker. 
2.2.3.1 CD44 
CD44 is a ubiquitous multi-structural and multi-functional cell surface glycoprotein 
involved in cell-cell adhesion, cell-matrix interactions, and cell migration. In stem cells CD44 
is widely expressed by many cell types and functions in cell adhesion, migration, homing, 
proliferation, survival and apoptosis. CD44 also plays critical roles in stemness regulation of 
cancer stem cells (CSCs). CD44 is expressed at the time of extracellular matrix formation in 
many sites during embryonic development. HA interacts with cells during embryonic 
development via the CD44 receptor, and these HACD44 interactions induce the activation of 
ERK to promote cell proliferation. CD44 also is expressed in various kinds of cancer cells 
and cancer stem cells. (Kenneth,2011), in his study of cell adhesion molecule CD44: its 
functional roles in prostate cancer proposed that CD44 is a cell adhesion glycoprotein and 
dysregulated CD44 expression characterizes most human cancers, including prostate cancer. 
From their experiment they conclude that CD44s reduces PCa growth and invasion in vitro, 
and possibly in vivo. And CD44v7-10 may be a target for chemosensitization, and plays a 
role in nutraceutical abrogation of tumor development.  
 
2.2.3.2 STRO-1 
  It is a murine IgM monoclonal Ab. STRO-1, produced from an immunization with a 
population of human CD34
+
 bone marrow cells which identify a cell surface antigen. It is 
express the stromal elements in human bone marrow. There are two dfferent types of 
population i.e. STRO-1
+
/Glycophorin A
+
 and 1
+
/Glycophorin A
- 
(Simmons, et al.,1991) .  
From bone marrow cells, the frequency of fibroblast colony-forming cells (CFU-F) is 
enriched approximately 100-fold in the STRO-1
+
/Glycophorin A
-
 population than in the 
STRO-1
+
/Glycophorin A
+
 population. A STRO-1
+
 is a subset of marrow cells  which is 
capable of differentiating into multiple mesenchymal lineages including hematopoiesis-
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supportive stromal cells with a vascular smooth muscle-like phenotype, adipocytes, 
osteoblasts and chondrocytes. STRO-1 is a valuable Ab for the identification, isolation and 
functional characterization of human bone marrow stromal cell. 
2.2.4 Neural stem cell marker: 
Neural stem cells are derived from neuron. 
2.2.4.1 Nestin:  
Nestin is a class VI intermediate filament protein.  It is expressed predominantly in 
the central nervous system (CNS) (Frederiksen et al.,1988) Nestin has been the most 
extensively used marker to identify CNS stem cells within various areas of the developing 
nervous system.Although nestin does not form intermediate filaments by itself in vitro it co-
assemble with vimentin or alpha-internexin to form and heterodimer . Heterodimer coiled-
coil complexes which is a intermediate filaments. Its transient expression has been suggested 
to be a major step in the neural differentiation pathway. Nestin is also expressed in non-
neural stem cell populations, such as pancreatic islet progenitors and hematopoietic 
progenitors  
2.2.4.2PSA-NCAM (Polysialic acid-neural cell adhesion molecule): 
It regulates the expression of neural cell adhesion molecule (NCAM). The isoforms of 
this marker have a critical role in neural developmental processes. The embryonic form of 
NCAM, PSA-NCAM, is highly polysialylated and expressed in the developing nervous 
system (Kiss et al., 2001). PSA-NCAM is related to synaptic rearrangement and plasticity. In 
the adult tissue, PSA-NCAM expression is restricted to regions that retain plasticity. A 
neuronal-restricted precursor is identify its high expression of PSA-NCAM and undergo self-
renewal and differentiate into multiple neuronal phenotypes .  PSA-NCAM
+
 neonatal brain 
precursors are restricted to a glial fate and thyroid hormone and modulate them into an 
oligodendrocyte fate. NCAM adhesiveness Polysialic acid modification significantly 
decreases and therefore, it is originally suggested that PSA-NCAM is a purely anti-adhesive 
factor that modulates cell-cell interactions in promoting brain plasticity.  PSA-NCAM 
interacts with secreted signaling molecules to perform an instructive role in development. 
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2.2.4.3 p75 Neurotrophin R (NTR):  
   p75 NTR is also named as low affinity nerve growth factor (NGF) . It is a type I 
receptor transmembrane protein that belongs to the tumor necrosis factor. It binds to NGF, 
BDNF, NT-3 and NT-4 equally (with low affinity).When p75NTR activate in the presence of 
Trk, enhances response to neurotrophin. TrkC receptors working together with p75 NTR 
serve the critical functions during the development of the nervous system (Hapner et al., 
1998). Neural crest stem cells (NCSCs) have isolate based on their surface expression of 
p75NTR (Morrison et al.,1999).Freshly isolated p75NTR
+
 NCSCs from peripheral nerve 
tissues can self-renew and generate neurons and glia both in vitro and in vivo. In addition, 
neuroepithelial-derived p75NTR
+
 cells are also able to differentiate into neurons, smooth 
muscle and Schwann cells in culture. Recently, p75 NTR has been used as a marker to 
identify mesenchymal precursors as well as hepatic stellate cells (Cassiman, et al. 2001).  
2.3 CD44 in oral cancer 
`Georgolios et al. (2006),  in his review focused on the role of CD44 adhesion 
molecule in carcinogenesis of the oral cavity with special emphasis on its potential use for 
diagnosis and prognosis of cancer of oral cavity.It is widely accepted today that the 
development of squamous cell tumors, including oral squamous cell carcinoma, is final 
outcome of multistep process characterized by progressive genetic alterations and gradual 
transition to malignancy (Alho et al.,1989).The early mutational events at genomic level are 
reflected in differential protein expression and subsequent molecular abnormalities at cellular 
level, in this way from normal to histopathologically established malignancy. The 
carcinogenesis is related to the dysregulation of cell adhesion and cell proliferation while 
alteration of angiogenetic function is a substantial part of tumor growth (Bartolazzi et 
al.,1996).The degree of glucosylation can affect the ligand binding features of the protein and 
alter its function. Observations indicate that changes in glucosylation of CD44 can affect its 
interaction with hyaluronic acid (HA). So this posttranslational modification may provide 
important regulatory mechanism for CD44 functioning (Georgolios et al.,2006). Over 
expression of CD44 is shown to be linked with poor outcome in squamous cell carcinomas of 
the oropharynx, hypopharynx, and larynx, whereas evidence concerning the oral cavity is 
slightly less assuring.[13] It has been speculated that CD44 can be used as a cancer stem cell 
marker, meaning that tumor cells expressing CD44 are capable of forming new tumors. 
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CHAPTER 3 
3.1 Objectives 
 To analyse the CD44 expression in different oral cancer tissue samples 
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CHAPTER 4 
4. MATERIALS AND METHODS 
 Three different groups of oral cancer cell tissues from different patients were take for 
immunohistochemical studies.i.e. Well differentiated, moderately differentiated, and poorly 
differentiated. 
4.1 MATERIALS 
4.1.1 CHEMICALS: 
1. xylene 
2. 100% ethanol 
3. 90% ethanol 
4. 70% ethanol 
5. Mayers Hematoxylin  
6. CD44 Primary antibody  
7. Polymer HRP 
8. DAB chromogen         
    4.1.2 MISCELLANEOUS  
1. Paraffin block                     
2. Slide 
3. Cover slip 
4. Paper bond 
5. Brush 
6. Oven 
7. Microtome 
8. Water bath 
9. Inverted Microscope 
4.2 Methods  
(A)Three different Groups (Well differentiated, moderately differentiated, poorly 
differentiated) tissue block was collected from Tridevi hospital kolkata. 
(B) 0.5 micron of thin section was prepared using microtome. 
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(C)Immunohistochemistry was done by following a standard protocol 
The slide was baked for 1 hour at 60⁰C temperature. Then wax was removed by 
xylene -1 & xylene-2 solution for 10 mins. After that It is kept in 100 % ethanol for 5 min, in 
90% ethanol for 5 min, 70% ethanol for 5 min sequentially .After that the slide was washed 
in with running tap water for 2 to 5 mins. To expose the antigen the tissue was Pre-treated in 
sub-boiling temperature for 20 min in EZ ready to use solution.  Buffer wash is done 3 times. 
after that it is kept in Peroxide block(100µl)for 10 min at room temp subsequently it was 
wash  with PBS buffer 3 times .Then it is kept in  Power block(100µl)10 min  room temp 
followed by 3 times PBS buffer wash. Then the tissue was incubated with primary CD44 
antibody for overnight at 4⁰c followed by 3 times PBS buffer wash. Then the tissue was 
incubated in Super enhancer (100µl) for 20 min at room temp and washed with PBS Buffer 3 
times.Tissue was kept in kept in Polymer HRP (100µl) for 30min at room te wamp and it was   
again washed in PBS buffer 3 times. 1 drop of liquid DAB (brown chromogen) was mixed in 
1 ml stable DAB buffer. Then 100µl DAB chromogen solution was added to the tissue and 
incubated for 5min at room temp. Then the tissue was washed in running tap water. The 
ttissue was counter stained with Hematoxylin counter stain (100µl) for 3 min at room temp.  
Again kept the slide in 70% ethanol for 5mins, 90% ethanol for 5 mins, 100% ethanol for 5 
mins. Finally the dehydrated slide was kept in xylene-2 for 10 min .Then the tissue were 
observed in inverted microscope to check the expression of CD44. 
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4.3 PROTOCOL FOR IMMUNOHISTOCHEMISTRY 
 
                                                        Xylene 1 (10 min) 
 
                                                         Xylene 2 (10 min) 
 
                                                          100 % ethanol ( 5 min) 
 
                                                            90% ethanol ( 5 min) 
 
                                                              70% ethanol ( 5 min) 
 
                                                  Running tap water( 2 to 5 min) 
 
              Pretreatment in subboiling temp, (for 20 min) in ready to use  EZ solution 
 
                                                          Buffer wash 3 times 
 
                                          Peroxide block (100µl)10 min at room temp 
 
                                                             Buffer wash 3 times 
 
                                             Power block(100µl)10 min rom temp 
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     Buffer wash 3 times 
                                                               
 
                                             Antibody incubation over night at 4⁰c 
 
                                                         Buffers wash 3 times 
 
                                      Super enhancer (100µl ) 20 min at room temp 
 
                                                        Buffer  wash 3 times 
 
                                         Polymer HRP (100µl)30min at room temp 
 
                                                             Buffer  wash 3 times 
 
                                                                DAB chromogen 
 
                                                             Running tap water 
 
                                  Haematoxylins counter stain (100µl) 3 min at room temp 
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70% ethanol (5 min) 
                                                          
                                                              90% ethanol (5min) 
 
                                                          100% ethanol (5 min) 
 
                                                              Xylene  (10 min) 
 
 
 
 
 
 
 
 
 
 
 
                                                
 
 
 
 
Observe under microscope 
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CHAPTER-5 
5. RESULT AND DISCUSSION 
Fig. 2: CD 44 expression in well differentiated oral cancer tissue Samples from 9 
patients  
 
          Patient-1                       patient-2                                 patient-3  
 
        Patient-4                       Patient-5                       Patient-6                        
 
           Patient-7                       Patient-8                       Patient-9  
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Fig.3: CD44 expression in moderately differentiated oral cancer tissue Samples from 5 
patients 
            
                Patient-10                                                Patient-11                      
             
                Patient-12                                                   Patient-13 
                                            
                                                          Patient 14 
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Fig.4 CD44 expression in poorly differentiated oral cancer tissue samples  of 2 patients 
          
                    Patient-15                                               Patient-16                                  
CD44 is a marker of stem cells and cancer stem cells that helps stem cell migration, 
homing, and differentiation, while in cancer, CD44 promotes metastasis, self-renewal, drug 
resistance and apoptosis resistance. For the 16 cases we studied, we observed the 
immunostaining degree for CD44 of the 3 different differentiation grades of OSCC. All cases 
of well-differentiated carcinomas presented the lowest immunostaining degree, the 
moderately ones presented a little higher immunostaining degree and the poorly differentiated 
were shown to present highest immunostaining degree. From the above study, we can assert 
that as poorly differentiated oral cancer tissue has high metastasis properties, high 
proliferation rate, highly invasive capacity as compare to the other two groups, the expression 
of CD44 stem cell marker is more in this groups which renders them to acquire the unique 
properties involved in invasion and metastasis. The well differentiated and moderately 
differentiated tissue has not very much aggressive & metastasis properties like poorly dif 
ferentiated tissue. So, in both case the CD44 expression is as low compare to the other two 
groups of tissues. Elevated expression of CD44 is also reported to be associated with poor 
outcome in other malignancies such as hematological malignancies, colorectal cancer, and 
gastric cancer. 
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CHAPTER-5 
5.1 CONCLUSION 
 Knowledge concerning biological activity of CD44 and its isoforms is not fully 
elucidated. However, as far as this glucoprotein is highly expressed in squamous epithelium, 
oral squamous cell carcinoma is expected to be one of most prevalent field for further 
investigation. The progress in study of adhesion molecules promise to be rapid during 
following years. Many opportunities for novel and more effective prognostic, diagnostic and 
therapeutic approaches involving CD44 are opening now. From the IHC study we concluded 
that the CD44 stem cell marker is highly expressed in poorly differentiated oral cancer tissue, 
moderately expressed in moderately differentiated tissue and the expression profile is 
relatively low in well differentiated oral cancer tissue.CD44 can be used as a prognostic 
marker in oral cancer. 
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